All In Biotech

Drug Trial Radar · NCT04298060

DAS181 for Patients With Severe Hospitalized Flu and SAD-RVs (COVID-19)

A Phase IIb Randomized Placebo-Controlled Study to Examine the Efficacy and Safety of DAS181 for the Treatment of Severe Influenza Infection

Last checked: Nov 19, 2026Latest source record: Jul 9, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

280

Planned (sponsor's estimate)

Start

Jul 2020

Primary completion

Mar 2021

Study completion Sep 2022

Sponsor

Lead sponsor
Ansun Biopharma, Inc.Industry
Sponsor type
Industry
First posted
Mar 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase IIb study consisting of two cohorts to evaluate efficacy, safety and pharmacokinetics of DAS181 in IFV infection. An approximate total of 280 subjects will be enrolled into this study.

Conditions

  • Influenza Infection
  • SAD-RV Infection and COVID-19

Interventions

  • DAS181Drug

    SD (4.5mg/day), HD (9mg/day)

  • PlaceboDrug

    Placebo 0mg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent of subjects who have returned to room airTime frame: 7 days
  2. Percent change of subjects return to baseline oxygen requirementTime frame: 7 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.